Patent approved also in India

The patent describing the use of light pulses to improve the efficiency of the technique and shorten imaging times has now also been granted in India. The patent has already been approved in Europe, South Korea, Australia, China, South Africa, USA and Japan and we are awaiting approval in Canada.

- The grant of the patent in India strengthens Lumito's patent portfolio: India could be a large potential future market for the company and the patent has potential in several application areas, comments Lumito's CEO Mattias Lundin.

Briefly about Lumito's worldwide patent family: Lumito's patents cover using nanoparticles as markers to create high-resolution images of tissues, for example in tumours. The technology has several potential applications, but as a first step Lumito has chosen to focus on digital pathology. Lumito has patented the technology with three worldwide patent families.

1. The first patent family protects the use of UCNPs (upconverting nanoparticles) for imaging in scattering materials. This family has patents approved in key regions worldwide and provides broad protection, even beyond medical use.
    
2. The second patent family, also with patents approved in key regions (see above), describes the use of light pulses to improve the efficiency of the technique and shorten imaging times. This patent family describes the use of light pulses to improve the efficiency of the technology and to reduce imaging times.
    
3. The third patent family describes the use of UCNP for imaging in particular tissue samples, specifically in pathology and tissue diagnostics. In August 2020, this third patent family was approved in Europe as the first region. The patent covers the application area in which Lumito will launch its first product. The patent protects Lumito's in vitro diagnostics with upconverting nanoparticles (UCNP).

For further information, please contact:

Mattias Lundin, CEO of Lumito, e-mail: ml@lumito.se.

Please also visit our website.

Lumito specializes in imaging technology within medical research and development. The technology is based on so called UCNP:s (Up Converting Nano Particles) and is aiming to increase image quality in biomedical applications.  Lumito´s IPR covers high-quality imaging of tissue, for instance in tumours, with UCNP:s as markers. The technology has several possible application areas, but Lumito has initially decided to focus on digital pathology. 

Lumito's share is traded under the ticker LUMITO on the Nordic Growth Market, NGM SME, where the Company's mentor is G&W Fondkommission, telephone: +468-503 000 50.

Tags: